The next generation impactor ^TM, or NGI ^TM, is a high performance cascade impactor for classifying aerosol particle into size fractions for testing meter-dose and dry-power inhaler and other inhaled drug delivery devices such as nebulizers and nasal sprays. MSP developed the NGI in conjunction with a consortium of 15 pharmaceutical companies, resulting in superior aerodynamic performance, low inter-stage losses, and user-friendly features, The NGI is recognized internationally both in the USP and the EP. It features removable collection cups, O-ring-free connections, and a micro-orifice collector that can be used in place of a final filter for most formulation. These features make the NGI an easy-to-use, efficient workstation, enabling 10 to 20 inhaler determinations per day with one impactor, resulting in less capital equipment and a cleaner, more efficient laboratory.
Designed specifically for the pharmaceutical industry for testing metered-dose inhalers (MDI), dry-power inhalers (DPI), nebulizer and nasal sprays.
Provides high-accuracy data and unappalled productivity.